5 results on '"Vij, Sanjiv"'
Search Results
2. Effect of a Recombinant Human Soluble Thrombomodulin on Mortality in Patients With Sepsis-Associated Coagulopathy: The SCARLET Randomized Clinical Trial
- Author
-
Vincent, Jean-Louis, Francois, Bruno, Zabolotskikh, Igor, Daga, Mradul Kumar, Lascarrou, Jean-Baptiste, Kirov, Mikhail Y., Pettila, Ville, Wittebole, Xavier, Meziani, Ferhat, Mercier, Emmanuelle, Lobo, Suzana M., Barie, Philip S., Crowther, Mark, Esmon, Charles T., Fareed, Jawed, Gando, Satoshi, Gorelick, Kenneth J., Levi, Marcel, Mira, Jean-Paul, Opal, Steven M., Parrillo, Joseph, Russell, James A., Saito, Hidehiko, Tsuruta, Kazuhisa, Sakai, Takumi, Fineberg, David, Bertuzzi, Romina, Bellomo, Rinaldo, Chapman, Marianne, Ernest, David, Fletcher, Jason, French, Craig, Gowardman, John, Shehabi, Yahya, Venkatesh, Bala, Walsham, James, Vij, Sanjiv, Chochrad, Didier, Creteur, Jacques, Devriendt, Jacques, Dive, Alain-Michel, Dugernier, Thierry, Foret, Frederic, Hoste, Eric, Jorens, Philippe, Simon, Marc, Spapen, Herbert, Dias, Fernando, Freire, Antonio, Lobo, Suzana Margarth, Simeonov, Georgi, Stefanov, Chavdar, Aslanian, Pierre, Berthiaume, Luc, Martin, Claudio, Chittock, Dean, Dhar, Anil, Doig, Christopher, Jones, Gwynne, Hall, Richard, Boyd, John, Shin, Phil, Wood, Gordon, Zarychanski, Ryan, Quinteros, Guillermo Agamenon, Gasparovic, Vladimir, Husedzinovic, Ino, Balik, Martin, Burget, Ivo, Dlouhy, Pavel, Pachl, Jan, Karlsson, Sari, Laru-Sompa, Raili, Parviainen, Ilkka, Ruokone, Esko, Skrifvars, Markus, Bohe, Julien, Dellamonica, Jean, Duguet, Alexandre, Durand-Gasselin, Jacques, Fiancette, Maud, Joannes-Boyau, Olivier, Lefrant, Jean-Yves, Mercat, Alain, Nseir, Saad, Quenot, Jean-Pierre, Reignier, Jean, Schwebel, Carole, Marx, Gernot, Zacharowski, Kai, Armaganidis, Apostolos, Komnos, Apostolos, Fejer, Csaba, Appajigol, Jayaprakash, Behera, Sarat Kumar, ChandraShekhar, Shivprasad, Chowdhury, Sanmay, D'costa, Pradeep Micheal, Gupta, Hari Shankar Shivkumar, Iyer, Shivakumar, Khan, Zafer A., Mehta, Minesh, Murthy, Sudharshan, Sahu, Sambit, Tewari, Reshma, Bar-Lavie, Yaron, Bregman, Gennady, Cohen, Jonathan, Eden, Arie, Einav-Bromiker, Sharon, Jakobson, Daniel, Nimrod, Adi, Beishuizen, Albertus, Gerritsen, Richard, Pickkers, Peter, Rozendaal, Wim, Schoonderbeek, F. J., Spoelstra-de Man, Angelique, van Zanten, Arthur R. H., Zijlstra, Jan G., Freebairn, Ross, Henderson, Seton, McArthur, Colin, Young, Paul, Mayorga, Manuel Jesus, Agafina, Alina S., Bubnova, Natalia, Gritsan, Alexey, Kameneva, Evgenia, Katasonov, Sergey P., Khasanova, Nina M., Kruberg, Lilly, Kulabukhov, Vladimir V., Lebedinskii, Konstantin, Spesivtsev, Yuri A., Rankovic, Zarko, Hong, Sang Bum, Kim, Min-Ja, Suh, Gee Young, Yoo, Chul-Gyu, Raventos, Antonio Artigas, Ferrer, Ricard, Vazquez, Rita Galeiras, Hernandez, Marianela, Piacentini, Enrique, Rodriguez Oviedo, Alejandro Hugo, Garcia, Miguel Sanchez, Chan, Ming-Cheng, Cheng, Kuo-Chen, Yu, Chong-Jen, Eddleston, Jane, Smith, Fang Gao, MacNaughton, Peter, Welters, Ingeborg, Allen, Karen, Bochicchio, Grant, Carlson, Richard, Eaton, Stephanie, Fink, Ryan, Gianatiempo, Carmine, Kapoor, Rajat, Kinasewitz, Gary, Koura, Firas, Krell, Kenneth, Martin, Niels, Nepal, Santosh, Pastores, Stephen M., Peltan, Ithan, Pullman, John, Seibert, Allan, Smith, Jason, Tennenberg, Steven, Wilhelm, Andrew, Zeno, Brian, Allton, Pam, Carruthers, David, Matsuki, Osamu, Kayanoki, Toshihiko, UCL - SSS/IREC/MEDA - Pôle de médecine aiguë, UCL - (MGD) Services des soins intensifs, Intensive care medicine, ACS - Atherosclerosis & ischemic syndromes, ACS - Diabetes & metabolism, UCL - (SLuc) Service de soins intensifs, Critical care, Anesthesiology, Peri-operative and Emergency medicine (CAPE), and SCARLET Trial Grp
- Subjects
Male ,medicine.medical_specialty ,Thrombomodulin ,COAGULATION ,PROTEIN ,Placebo ,01 natural sciences ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,Randomized controlled trial ,law ,Internal medicine ,Intensive care ,Cause of Death ,Sepsis ,medicine ,Clinical endpoint ,Coagulopathy ,Humans ,030212 general & internal medicine ,International Normalized Ratio ,Treatment Failure ,0101 mathematics ,Infusions, Intravenous ,Original Investigation ,Aged ,business.industry ,Mortality rate ,010102 general mathematics ,Anticoagulants ,General Medicine ,Disseminated Intravascular Coagulation ,Blood Coagulation Disorders ,Middle Aged ,medicine.disease ,Recombinant Proteins ,3. Good health ,Injections, Intravenous ,Female ,Human medicine ,business ,Packed red blood cells - Abstract
IMPORTANCE Previous research suggested that soluble human recombinant thrombomodulin may reduce mortality among patients with sepsis-associated coagulopathy.OBJECTIVE To determine the effect of human recombinant thrombomodulin vs placebo on 28-day all-cause mortality among patients with sepsis-associated coagulopathy.DESIGN, SETTING, AND PARTICIPANTS The SCARLET trial was a randomized, double-blind, placebo-controlled, multinational, multicenter phase 3 study conducted in intensive care units at 159 sites in 26 countries. All adult patients admitted to one of the participating intensive care units between October 2012 and March 2018 with sepsis-associated coagulopathy and concomitant cardiovascular and/or respiratory failure, defined as an international normalized ratio greater than 1.40 without other known etiology and a platelet count in the range of 30 to 150 x 10(9)/L or a greater than 30% decrease in platelet count within 24 hours, were considered for inclusion. The final date of follow-up was February 28, 2019.INTERVENTIONS Patients with sepsis-associated coagulopathy were randomized and treated with an intravenous bolus or a 15-minute infusion of thrombomodulin (0.06mg/kg/d [maximum, 6mg/d]; n=-395) or matching placebo (n=-405) once daily for 6 days.MAIN OUTCOME AND MEASURES The primary end pointwas 28-day all-cause mortality.RESULTS Among 816 randomized patients, 800 (mean age, 60.7 years; 437 [54.6%] men) completed the study and were included in the full analysis set. In these patients, the 28-day all-cause mortality rate was not statistically significantly different between the thrombomodulin group and the placebo group (106 of 395 patients [26.8%] vs 119 of 405 patients [29.4%], respectively; P=-.32). The absolute risk difference was 2.55%(95% CI, -3.68% to 8.77%). The incidence of serious major bleeding adverse events (defined as any intracranial hemorrhage; life-threatening bleeding; or bleeding event classified as serious by the investigator, with administration of at least 1440mL [typically 6 units] of packed red blood cells over 2 consecutive days) was 23 of 396 patients (5.8%) in the thrombomodulin group and 16 of 404 (4.0%) in the placebo group.CONCLUSIONS AND RELEVANCE Among patients with sepsis-associated coagulopathy, administration of a human recombinant thrombomodulin, compared with placebo, did not significantly reduce 28-day all-cause mortality.TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT01598831
- Published
- 2019
- Full Text
- View/download PDF
3. Intensive care discharge delay is associated with increased hospital length of stay: A multicentre prospective observational study.
- Author
-
Tiruvoipati, Ravindranath, Botha, John, Fletcher, Jason, Gangopadhyay, Himangsu, Majumdar, Mainak, Vij, Sanjiv, Paul, Eldho, Pilcher, David, and null, null
- Subjects
INTENSIVE care units ,LENGTH of stay in hospitals ,HOSPITAL admission & discharge ,MEDICAL decision making ,HOSPITAL patients - Abstract
Background: Some patients experience a delayed discharge from the intensive care unit (ICU) where the intended and actual discharge times do not coincide. The clinical implications of this remain unclear. Objective: To determine the incidence and duration of delayed ICU discharge, identify the reasons for delay and evaluate the clinical consequences. Methods: Prospective multi-centre observational study involving five ICUs over a 3-month period. Delay in discharge was defined as >6 hours from the planned discharge time. The primary outcome measure was hospital length stay after ICU discharge decision. Secondary outcome measures included ICU discharge after-hours, incidence of delirium, survival to hospital discharge, discharge destination, the incidence of ICU acquired infections, revocation of ICU discharge decision, unplanned readmissions to ICU within 72 hours, review of patients admitting team after ICU discharge decision. Results: A total of 955 out of 1118 patients discharged were included in analysis. 49.9% of the patients discharge was delayed. The most common reason (74%) for delay in discharge was non-availability of ward bed. The median duration of the delay was 24 hours. On univariable analysis, the duration of hospital stay from the time of ICU discharge decision was significantly higher in patients who had ICU discharge delay (Median days-5 vs 6; p = 0.003). After-hours discharge was higher in patients whose discharge was delayed (34% Vs 10%; p<0.001). There was no statistically significant difference in the other secondary outcomes analysed. Multivariable analysis adjusting for known confounders revealed delayed ICU discharge was independently associated with increased hospital length of stay. Conclusion: Half of all ICU patients experienced a delay in ICU discharge. Delayed discharge was associated with increased hospital length of stay. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
4. Early mobilization on continuous renal replacement therapy is safe and may improve filter life
- Author
-
Wang, Yi, primary, Haines, Terry P, additional, Ritchie, Paul, additional, Walker, Craig, additional, Ansell, Teri A, additional, Ryan, Danielle T, additional, Lim, Phaik-Sim, additional, Vij, Sanjiv, additional, Acs, Rebecca, additional, Fealy, Nigel, additional, and Skinner, Elizabeth H, additional
- Published
- 2014
- Full Text
- View/download PDF
5. Prognostic factors associated with hospital survival in comatose survivors of cardiac arrest.
- Author
-
Sathianathan K, Tiruvoipati R, and Vij S
- Abstract
Aim: To identify patient, cardiac arrest and management factors associated with hospital survival in comatose survivors of cardiac arrest., Methods: A retrospective, single centre study of comatose patients admitted to our intensive care unit (ICU) following cardiac arrest during the twenty year period between 1993 and 2012. This study was deemed by the Human Research Ethics Committee (HREC) of Monash Health to be a quality assurance exercise, and thus did not require submission to the Monash Health HREC (Research Project Application, No. 13290Q). The study population included all patients admitted to our ICU between 1993 and 2012, with a discharge diagnosis including "cardiac arrest". Patients were excluded if they did not have a cardiac arrest prior to ICU admission (i.e., if their primary arrest was during their admission to ICU), or were not comatose on arrival to ICU. Our primary outcome measure was survival to hospital discharge. Secondary outcome measures were ICU and hospital length of stay (LOS), and factors associated with survival to hospital discharge., Results: Five hundred and eighty-two comatose patients were admitted to our ICU following cardiac arrest, with 35% surviving to hospital discharge. The median ICU and hospital LOS was 3 and 5 d respectively. There was no survival difference between in-hospital and out-of-hospital cardiac arrests. Males made up 62% of our cardiac arrest population, were more likely to have a shockable rhythm (56% vs 37%, P < 0.001), and were more likely to survive to hospital discharge (40% vs 28%, P = 0.006). On univariate analysis, therapeutic hypothermia, regardless of method used (e.g., rapid infusion of ice cold fluids, topical ice, "Arctic Sun", passive rewarming, "Bair Hugger") and location initiated (e.g., pre-hospital, emergency department, intensive care) was associated with increased survival. There was however no difference in survival associated with target temperature, time at target temperature, location of initial cooling, method of initiating cooling, method of maintaining cooling or method of rewarming. Patients that survived were more likely to have a shockable rhythm (P < 0.001), shorter time to return of spontaneous circulation (P < 0.001), receive therapeutic hypothermia (P = 0.03), be of male gender (P = 0.006) and have a lower APACHE II score (P < 0.001). After multivariate analysis, only a shockable initial rhythm (OR = 6.4, 95%CI: 3.95-10.4; P < 0.01) and a shorter time to return of spontaneous circulation (OR = 0.95, 95%CI: 0.93-0.97; P < 0.01) was found to be independently associated with survival to hospital discharge., Conclusion: In comatose survivors of cardiac arrest, shockable rhythm and shorter time to return of spontaneous circulation were independently associated with increased survival to hospital discharge.
- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.